InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,658.00
(
0.32%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.25
(
0.35%
)
Bitcoin
62,748.16
(
-0.48%
)
Post# of 273
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 145
Posts 27566
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: None

Tuesday, 03/17/2015 4:20:31 PM

Tuesday, March 17, 2015 4:20:31 PM

Post# of 273
OpthaliX, Inc., is currently testing CF101 in a Phase 2 trial for the treatment of glaucoma, with results expected to be released in the second half of 2015.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent MIGI News
More MIGI News
InvestorsHub NewsWire

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Start posting your company's news
Only $200 per official company press release!